ERBB2 and breast cancer: The inhibiting of Fibroblast Growth Factor Receptor 4 (FGFR4) mediated by m6A hypomethylation significantly suppress GSH synthesis and efflux of Fe2+ through β-catenin/TCF4-SLC7A11/FPN1 signaling pathway, which trigger the excessive production of ROS and abnormal iron pool accumulation in Her-2 positive breast cancer (Zou et al., 2022).